By Fineline Cube NeuShen Therapeutics announced the successful closing of an oversubscribed Series B financing round exceeding USD 80 million, reinforcing investor confidence in its differentiated CNS pipeline. Led by a leading industrial capital investor with participation from B Capital, Legend Capital, Matrix Partners China, Zhenmai Capital, and SDIC Venture Capital — plus continued follow‑on investment from existing shareholder Lilly Asia Ventures (LAV) — the round ranks among the larger recent private financings dedicated to central nervous system drug discovery.
Financing Terms at a Glance
| Item | Detail |
|---|---|
| Company | NeuShen Therapeutics |
| Round | Series B, oversubscribed |
| Size | Exceeding USD 80 million |
| Lead Investor | Leading industrial capital investor |
| Participating Institutions | B Capital, Legend Capital, Matrix Partners China, Zhenmai Capital, SDIC Venture Capital |
| Existing Shareholder | Lilly Asia Ventures (LAV) added to its investment |
| Use of Proceeds | Expand CNS innovative pipeline; accelerate global clinical development of core programs; explore breakthrough therapies for major unmet medical needs |
Pipeline Snapshot – Three Core Clinical Programs
| Program | Mechanism | Indication | Stage |
|---|---|---|---|
| NS‑079 | Non‑hallucinogenic 5‑HT2A receptor partial agonist | Depressive disorders | First‑in‑human trial initiated in Australia |
| NS‑136 (laviclidine) | Novel highly selective M4 receptor positive allosteric modulator | Acute‑phase schizophrenia | Phase II in China |
| NS‑136 (laviclidine) | Same mechanism | Agitation symptoms associated with Alzheimer’s disease | Phase II approved by NMPA and U.S. FDA |
| NS‑041 (zolankalner) | Highly selective KCNQ2/3 channel agonist | Focal‑onset seizures | Phase II multicenter trial, patient enrollment underway |
| NS‑041 (zolankalner) | Same mechanism | Major depressive disorder | Phase II actively being prepared |
All three core programs are in clinical development, with mechanisms spanning serotonergic, cholinergic, and ion‑channel targets — a breadth that gives NeuShen multiple independent shots at breakthrough CNS therapies.
Market Impact & Outlook
- Investor validation: An oversubscribed round backed by both industrial capital and marquee financial investors — with LAV increasing its stake — signals strong external confidence in NeuShen Therapeutics’ scientific platform
- Global execution: With a first‑in‑human trial running in Australia and Phase II approvals secured from both the NMPA and U.S. FDA for NS‑136, the company is executing a genuinely international CNS development strategy
- Unmet‑need focus: Schizophrenia agitation, Alzheimer’s‑related agitation, focal seizures, and depression represent indications with large patient populations and persistent treatment gaps — a foundation for differentiated commercial value
- Capital runway: The USD 80‑plus million proceeds provide NeuShen the resources to advance multiple Phase II programs concurrently, a rarity for private CNS‑focused biotechs in the current funding environment
Forward‑Looking Statements — This brief contains forward‑looking statements regarding the use of proceeds, clinical development timelines, regulatory outcomes, and commercial potential of NeuShen Therapeutics’ CNS pipeline. Actual results may differ materially due to scientific, clinical, regulatory, competitive, and market risks. No investment decision should be made solely on the basis of this brief.-Fineline Info & Tech